Effect of Bupropion on second generation antipsychotic induced weight gain and Melanocyte stimulating hormone (MSH) in patients with schizophrenia.

Not Applicable

• Conditions: Health Condition 1: F209- Schizophrenia, unspecified

• Registration Number: CTRI/2023/08/057007
• Lead Sponsor: Central Institute of Psychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

In-patients satisfying the ICD-11 DCR criteria for schizophrenia.

First episode schizophrenia (2years)

Age 18-50yrs of both sexes.

BMI greater than or equal to 25 kg/m2

CDSS score <6 to rule out secondary negative symptoms.

Those who give written informed consent for participating in the study.

Exclusion Criteria

Any other drug(except for Antipsychotics) that can cause weight gain.

Patients on 1st generation antipsychotics and or on 1st generation depot antipsychotics.

Co-morbid endocrine and/or cardiovascular conditions.

Any other major co-morbid psychiatric diagnosis and substance dependence excluding nicotine and caffeine.

Known hypersensitivity to Tab. Bupropion or any of its components.

Deranged liver function test ( ALT greater than/equal to 180 IU/L and/or AST greater than/equal to 140 IU/L)

Significant current/past medical or neurological illness including severe hepatic disease and history of severe head injury.

Patients currently receiving ECT.

Treatment resistant schizophrenia patients or patients on clozapine.

History of suicidality (intent/attempt)

QTc interval greater than/equal to 450ms in males and greater than/equal to 470ms in females on Electrocardiogram (ECG).

Pregnancy.

Study & Design

• Study Type: Interventional
• Study Design: Not specified